PYPD News and Press, PolyPid Ltd. From 12/16/25

PETACH TIKVA, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directo...

2025-12-10 16:42:55 ET PolyPid Ltd. (PYPD) Discusses the Science and Business Case for D-PLEX100 in Tackling Surgical Site Infections December 10, 2025 11:30 AM EST... Read the full article on Seeking Alpha For further details see: PolyPid Ltd. (PYPD) Discusses the Science a...

PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a formal pre-New Drug Application (“NDA...

PETACH TIKVA, Israel, Nov. 25, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will participate in a virtual Key Opinion Leader (KOL) event ho...

2025-11-12 12:51:39 ET PolyPid Ltd. (PYPD) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Dikla Akselbrad - CEO & Director Ori Warshavsky - Chief Operating Officer - US Jonny Missulawin - Chief Financial Officer ... Read the ...

2025-11-12 07:35:00 ET More on PolyPid Seeking Alpha’s Quant Rating on PolyPid Historical earnings data for PolyPid Financial information for PolyPid Read the full article on Seeking Alpha For further details see: PolyPid GAAP EPS of -$0.37...

Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive Phase 3 Trial Results Company Continues to Advance Towards ...

RWE AG ADR (RWEOY) is expected to report $0.16 for Q3 2025 Hillenbrand Inc (HI) is expected to report $0.62 for Q4 2025 Ardent Health Inc. (ARDT) is expected to report $0.42 for Q3 2025 Quince Therapeutics Inc. (QNCX) is expected to report $-0.2 for Q3 2025 GlobalFoundries Inc. (G...

PETACH TIKVA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company focused on improving surgical outcomes, today announced that D-PLEX₁₀₀, the company’s lead candidate, has been named...

PETACH TIKVA, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2025 financial results and operational highlights before...